Agenus Inc (AGEN) reports a narrowed net loss and strategic advancements despite revenue decline and cash pressure in Q1 2025 ...

Mineralys Therapeutics reports strong Q1 2025 results, announcing pivotal trial success for lorundrostat, a $201M equity raise, and progress toward ...

Sangamo Therapeutics Inc (SGMO) secures a major deal with Eli Lilly and advances its pipeline, while navigating funding needs ...

Q1 2025 Earnings Call Transcript May 12, 2025 FibroGen, Inc. misses on earnings expectations. Reported EPS is $-0.16 EPS, ...

The FDA will issue a decision on the BLA for RGX-121 by November, which if positive, could make it the first gene therapy for Hunter syndrome.

Welcome to FibroGen first quarter 2025 earnings conference call. (Operator Instructions). Please be advised today's conference is being recorded. I would not like to end the conference over to your ...

Meaningful extension of cash runway guidance from H2 2027 to H2 2028 following strategic decision to pursue partnership opportunities for naporafenib SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Erasca ...

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for central nervous system and oncology-related conditions. Its lead candidates, NDV-01 ...

Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance Net cash held in China at closing now esti ...

Financially, Creative Medical has limited cash reserves, high cash burn, and will likely need dilutive financing. Click here ...

Q1 2025 Earnings Call Transcript May 11, 2025 Operator: Greetings, and welcome to KORU Medical Systems First Quarter 2025 ...

Clinical data on track for Q4 2025 from Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored Phase 0/1 trial into newly diagnosed glioblastoma pa ...